Revolutionizing cancer treatment by rethinking drug delivery
We are translating cancer research into efficient, practical new medicines using Utterbodies
We are translating cancer research into efficient, practical new medicines using Utterbodies
Utter Therapeutics boasts a remarkable track record in targeted drug delivery to tumors. Our team, which includes the founders of RayzeBio, now part of Bristol Meyers Squibb, is at the forefront of cancer research and clinical translation. We take educated risks, leveraging our scientific and clinical experience to improve patient outcomes
Utter Therapeutics is committed to integrity, excellence, and innovation. Our appreciation for the nuances of drug development enables us to efficiently execute, accelerating the development of new medicines
Utter Therapeutics
Copyright © 2024 Utter Therapeutics - All Rights Reserved. Info@UtterTx.com
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.